Hospital medication Top50 variety growth PK up more than 30% accounted for ten seats!

Pharmaceutical network August 25th, "4 plus 7" after the ordinary generic drugs are being collected to push into the era of micro-profits.
"Big Shuffle" result: high-end generic drugs still have a chance, pharmaceutical giants occupy the market in volume for price, but a large number of low-end generic drugs that do not pass the consistent evaluation will be eliminated, innovative drugs will accelerate the progress of national policies.
, according to domestic sample hospital statistics, the total sales of TOP50 varieties of drug use in 2019 amounted to 76.414 billion yuan.
, the purchase amount of the top 10 varieties accounted for 10.2% of the total amount, the top 20 varieties accounted for 16.0%, the top 30 varieties accounted for 22.1%, the top 40 varieties accounted for 26.6%, and the top 50 varieties accounted for 30%.
TOP50 varieties cover the fields: anti-infective drugs amounted to 13.999 billion yuan, blood and hematopoirty drugs 12.911 billion yuan, anti-tumor drugs 11.403 billion yuan, digestive system drugs 7.107 billion yuan, nervous system drugs 5,065 million yuan, other areas (immunomodulators, biotechnology drugs, cardiovascular system medications, endocrine and metabolic regulatory drugs, respiratory drugs, narcotic drugs and their auxiliary gloating agents, bone and muscle drugs, nutritional drugs, psychotic disorders drugs) totaled 25.929 billion yuan.
Analysis of the growth rate of generic name varieties in sample hospitals shows that there are 10 products with growth rates of more than 30%, 18 products with growth rates of 20% to 30%, 9 products with growth rates of 1% to 10%, and the amount of drug use of other products has decreased to varying degrees.
from the 2019 sample hospital data, the main reasons for the rebound in growth are: the dynamic adjustment of the medical insurance catalogue in the past two years, the inclusion of varieties ushered in the release volume;
of the above-mentioned products has strongly stimulated the growth of the overall market of sample hospitals, but also reflects the competitiveness of the core products of domestic sample hospitals.
growth rate of more than 30% products, a variety increased 989.4% in 2019, sample hospital drug use amount TOP50 products and growth rate of more than 30% are: drug use amount of more than 3 billion yuan products: yew alcohol 3,053 million yuan, growth rate of 40.86%.
products with a drug use amounting to 1 billion to 2 billion yuan: Quto Zhu single resistance 1,945 million yuan, an increase of 48.22%; polyethyl glycol recombinant human granulocyte collection stimulation factor of 1.705 billion yuan, an increase of 73.50%; butyl benzene 1.589 billion yuan, an increase of 30.49%; Logging beads were resistant to 1.555 billion yuan, an increase of 55.62 percent, iodized kesha alcohol was 1,466 million yuan, an increase of 38.44 percent, recombinant human plateplate production was 1,257 million yuan, an increase of 42.28 percent, and Oghitini was 1,004 million yuan, an increase of 989.4 percent.
products with a drug use amounting to less than 1 billion yuan were: 955 million yuan, an increase of 36.86 percent, and 933 million yuan of acetylcysteine, an increase of 47.93 percent.
10% to 30% growth rate products in 2019, sample hospital drug use amount TOP50 products and growth rate of 10% to 30% of the products are: drug use amount of more than 2 billion yuan are 2: Dzosin 2.196 billion yuan, growth rate of 17.87%;
products with a drug use amounting to 1 billion to 2 billion yuan are: Moxixa Star 1.882 billion yuan, an increase of 15.88%; 22%; Pirasirintambatan 1,681 million yuan, up 11.68%; Esomeilatan 1,661 million yuan, up 19.83%; Budinide 1,531 million yuan, up 15.2%; propofol 15.2% 500 million yuan, growth 12.32 percent; Tekmos 1.502 billion yuan, up 15.35 percent; Reberazole 1.499 billion yuan, up 15.59 percent; Lytoxi monoantitor 1.424 billion yuan, up 16.91 percent; left oxyfluorosa star 1 409 million yuan, an increase of 11.3%; Akapo sugar of 1,317 million yuan, an increase of 13.74%; intestinal nutrients of 1,156 million yuan, an increase of 12.91%; and a growth rate of 1,019 million yuan, or 17.85 percent.
products with sales of less than 1 billion yuan were: Liang Proprilin 997 million yuan, an increase of 21.01 percent, and Goscherrelin 910 million yuan, an increase of 17.64 percent.
growth rate of 1% to 10% products in 2019, sample hospital drug use amount TOP50 products and growth rate of 1% to 10% are: sample hospital drug use amount of more than 3 billion yuan has one: sodium chloride 3.208 billion yuan, growth rate of 8.14%.
products with a sample hospital amount of 1 billion to 2 billion yuan were: Voliconazole 1.717 billion yuan, an increase of 9.97 percent, and compound amino acids of 1.355 billion yuan, an increase of 9.54 percent. Omeprazole was 1.205 billion yuan, up 7.11 percent, Osali platinum was 1.105 billion yuan, up 9.7 percent, and snake venom blood coagulase was 1,009 million yuan, up 1.28 percent.
sample hospitals used drugs amounting to less than 1 billion yuan of products are three: Capertabin 989 million yuan, an increase of 2.02%;
growth rate decreased products in 2019, sample hospital drug use TOP50 products and the growth rate decreased are: sample hospital drug sales of more than 1.5 billion yuan: Atovastatin 1,969 million yuan, down 18.33 Clopidogre, 1.89 billion yuan, down 20.99 percent; Vitolazo, 1,624 million yuan, down 3.88 percent; and Pemide, 1.599 billion yuan, down 0.95 percent.
sample hospital drugs amounting to 1 billion to 2 billion yuan products: Dossytasai 1.337 billion yuan, down 3.03 percent; Orasitan 1.28 billion yuan, down 13.84 percent; Teo 1.28 billion yuan, down 1.16 percent; Endi Kavey was 1,264 million yuan, down 30.75 percent, Fluorobie was 1,189 million yuan, down 11.48 percent, Forrest was 1,054 million yuan, down 18.6 percent, and Lansolazole was 1,033 million yuan, down 10.2 percent.
sample hospital drug use amount of less than 1 billion yuan products: Ruishuvastatin 915 million yuan, a decrease of 22.72 percent.
.